Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • HCW Biologics' Cash from Financing Activities fell 3222.9% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year increase of 4652.97%. This contributed to the annual value of $15.6 million for FY2024, which is 10721790.28% up from last year.
  • HCW Biologics' Cash from Financing Activities amounted to $1.9 million in Q3 2025, which was down 3222.9% from $4.6 million recorded in Q2 2025.
  • HCW Biologics' Cash from Financing Activities' 5-year high stood at $98.5 million during Q4 2021, with a 5-year trough of -$48.4 million in Q3 2021.
  • Its 5-year average for Cash from Financing Activities is $4.1 million, with a median of $6000.0 in 2022.
  • In the last 5 years, HCW Biologics' Cash from Financing Activities tumbled by 88393.38% in 2021 and then surged by 22202277.75% in 2024.
  • Quarter analysis of 5 years shows HCW Biologics' Cash from Financing Activities stood at $98.5 million in 2021, then crashed by 100.04% to -$39846.0 in 2022, then skyrocketed by 61.73% to -$15250.0 in 2023, then surged by 43540.29% to $6.6 million in 2024, then tumbled by 71.35% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $4.6 million for Q2 2025, and -$53103.0 during Q1 2025.